Table 2. Comparison of key outcome... | American Society of Hematology

Table 2.

Comparison of key outcome measures in patients treated with caplacizumab vs standard of care

Parameter	Caplacizumab observational experience A¹⁴	Caplacizumab observational experience B⁴	Caplacizumab observational experience C⁵	Caplacizumab observational experience D⁶	Pooled RCT placebo arms^1,2	Harvard collaborative without caplacizumab^11,17,18
Number of subjects	60	90	85	44	112	124
Mortality per episode (%)	1.7	1.1	6.0	4.5	4.5	3.7
Number of TPE sessions	9 (2-41)^a	5 (4-7)	7 (5-14)	8.5 (6-12.5)	10.2^b	15 (8-23)
Hospital LOS (days)	18 (5-79)^a	13 (9-19)	12 (8-24)	12 (9-15)	12 (4-53)^c	12 (8-20)

Parameter	Caplacizumab observational experience A¹⁴	Caplacizumab observational experience B⁴	Caplacizumab observational experience C⁵	Caplacizumab observational experience D⁶	Pooled RCT placebo arms^1,2	Harvard collaborative without caplacizumab^11,17,18
Number of subjects	60	90	85	44	112	124
Mortality per episode (%)	1.7	1.1	6.0	4.5	4.5	3.7
Number of TPE sessions	9 (2-41)^a	5 (4-7)	7 (5-14)	8.5 (6-12.5)	10.2^b	15 (8-23)
Hospital LOS (days)	18 (5-79)^a	13 (9-19)	12 (8-24)	12 (9-15)	12 (4-53)^c	12 (8-20)

All values reported as median (interquartile range) unless otherwise noted.

Reported as median (range).

Weighted mean from both studies.

Reported in HERCULES trial only.

LOS, length of stay; NR, not reported.